Post by icemandios on Feb 18, 2021 14:01:23 GMT
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the following upcoming investor conferences:
SVB Leerink Annual Global Healthcare Conference: Friday, February 26, 2021 at 10:40 am ET
HC Wainwright Global Life Sciences Conference: on-demand beginning at 7:00 am ET on March 9, 2021
Oppenheimer 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 11:20 am ET
The presentations can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com .
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial products, Gvoke® in the U.S. and Ogluo™ in Europe. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the following upcoming investor conferences:
SVB Leerink Annual Global Healthcare Conference: Friday, February 26, 2021 at 10:40 am ET
HC Wainwright Global Life Sciences Conference: on-demand beginning at 7:00 am ET on March 9, 2021
Oppenheimer 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 11:20 am ET
The presentations can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com .
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial products, Gvoke® in the U.S. and Ogluo™ in Europe. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system